Artemio Mendoza, MD
Infectious Disease · Dover, NHNPI 1235211558
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $885 of the $1,351 with a category attached, or 65.5%. 11 manufacturers reported payments, led by Janssen Products, LP at 26.3% of the total. Reporting peaked in 2019 at $674 and has fallen 82.1% since, to $121 in 2025. Among infectious disease clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $37.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Products, LP$355
- AbbVie$235
- Gilead$171
- Insmed, Inc.$131
- Johnson & Johnson$126
- Astellas Pharma US Inc$96
- plus $236 from 5 others
What the payments were for
- Food & beverage$88566%
- Education$46534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Products, LP | 4 | $355 |
| AbbVie | 2 | $235 |
| Gilead | 2 | $171 |
| Insmed, Inc. | 4 | $131 |
| Johnson & Johnson | 11 | $126 |
| Astellas Pharma US Inc | 3 | $96 |
| Shionogi Inc | 1 | $76 |
| Viiv Healthcare Company | 3 | $50 |
| Merck | 3 | $44 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $44 |
| Theratechnologies Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,351 in reported general payments places this provider in the 95th percentile of 33 infectious disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $186,729 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 37 | $152,928 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 30 | $126,625 |
| JulucaDolutegravir/Rilpivirine | 29 | $117,385 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $37,922 |
| MytesiCrofelemer | 11 | $27,173 |
| Etravirine | 12 | $12,751 |
| Darunavir | 12 | $9,642 |
| MyrbetriqMirabegron | 28 | $6,441 |
| Rifampin | 20 | $1,103 |
| Doxycycline Monohydrate | 19 | $760 |
| Ritonavir | 12 | $752 |
| Ethambutol Hcl | 30 | $665 |
| Amoxicillin | 15 | $384 |
| Levetiracetam | 13 | $315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $171 | $313,35476 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Dovato | $50 | $308,23579 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $6,44128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 infectious disease providers in New Hampshire.
Other infectious disease in Dover
- Elizabeth TalbotLebanon$56K
- Antonia AltomareLebanon$1K
- Alexander GranokMerrimack$866
- Dafer Al-HaddadinPortsmouth$784
- Roma Cruz-KingMerrimack$717
- Ronaldo PatiagPortsmouth$712
- David ItkinPortsmouth$585
- Gabriela Andujar VazquezLebanon$514
- Jennifer GittzusConcord$300
- Ambreen KhalilKeene$274
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.